GRTS Stock Overview
A clinical-stage biotechnology company, engages in developing vaccine-based immunotherapy candidates against cancer and infectious diseases.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
Gritstone bio, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.70 |
| 52 Week High | US$3.33 |
| 52 Week Low | US$0.67 |
| Beta | 0.65 |
| 1 Month Change | -26.97% |
| 3 Month Change | -67.75% |
| 1 Year Change | -70.46% |
| 3 Year Change | -93.00% |
| 5 Year Change | -92.73% |
| Change since IPO | -95.06% |
Recent News & Updates
Recent updates
Gritstone bio: GRANITE Cancer Vaccine Data Overshadowed By Offering
Apr 07Gritstone bio, Inc. (NASDAQ:GRTS) Analysts Just Slashed This Year's Revenue Estimates By 40%
Aug 14
Gritstone bio: Early Data For SLATE Candidate Sets Up 2023 Catalyst
Sep 26Gritstone reaches six-month high on publication of data for cancer vaccine
Aug 16Gritstone bio announces $80M credit facility
Jul 21Is Gritstone bio (NASDAQ:GRTS) In A Good Position To Invest In Growth?
Jul 07Gritstone bio: Potential To Advance Colorectal Cancer Treatment
Jul 05Gritstone bio: Investing In A Premium mRNA Technology At A Discounted Valuation
Jun 14Some Analysts Just Cut Their Gritstone bio, Inc. (NASDAQ:GRTS) Estimates
Mar 17We're Not Very Worried About Gritstone bio's (NASDAQ:GRTS) Cash Burn Rate
Mar 05Gritstone: Why The Stock Fell On Positive Data
Jan 18Gritstone bio (NASDAQ:GRTS) Is In A Strong Position To Grow Its Business
Nov 23Gritstone Poised To Dominate mRNA Market
Nov 08Shareholder Returns
| GRTS | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -12.1% | 2.4% | -0.6% |
| 1Y | -70.5% | 6.7% | 21.7% |
Return vs Industry: GRTS underperformed the US Biotechs industry which returned 6.3% over the past year.
Return vs Market: GRTS underperformed the US Market which returned 22.4% over the past year.
Price Volatility
| GRTS volatility | |
|---|---|
| GRTS Average Weekly Movement | 19.3% |
| Biotechs Industry Average Movement | 10.6% |
| Market Average Movement | 5.8% |
| 10% most volatile stocks in US Market | 15.6% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: GRTS's share price has been volatile over the past 3 months.
Volatility Over Time: GRTS's weekly volatility (19%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 231 | Andrew Allen | gritstonebio.com |
Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing vaccine-based immunotherapy candidates against cancer and infectious diseases. Its primary product candidate is GRANITE, an individualized immunotherapy candidate, which is in Phase 2/3 clinical trials for the treatment of microsatellite stable colorectal cancers; and has completed Phase 1/2 clinical trials for treating solid tumors. The company is also developing SLATE, an off-the-shelf immunotherapy candidate, which is in Phase 2 clinical trials for the treatment of metastatic solid tumors.
Gritstone bio, Inc. Fundamentals Summary
| GRTS fundamental statistics | |
|---|---|
| Market cap | US$79.72m |
| Earnings (TTM) | -US$144.89m |
| Revenue (TTM) | US$15.64m |
4.9x
P/S Ratio-0.5x
P/E RatioIs GRTS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GRTS income statement (TTM) | |
|---|---|
| Revenue | US$15.64m |
| Cost of Revenue | US$129.71m |
| Gross Profit | -US$114.07m |
| Other Expenses | US$30.83m |
| Earnings | -US$144.89m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.33 |
| Gross Margin | -729.18% |
| Net Profit Margin | -926.25% |
| Debt/Equity Ratio | 288.8% |
How did GRTS perform over the long term?
See historical performance and comparison